Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Investors: Take Advantage of Double Fed Tax Credits on Critical Minerals Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Beyond Air Inc XAIR

Healthcare Medical Devices
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. The Company’s LungFit platform can be used to treat patients on ventilators that require NO, as well as patients with chronic or acute severe lung infections through delivery through a breathing mask or similar apparatus. The Company’s areas of focus with LungFit are persistent pulmonary hypertension of the newborn (PPHN), viral community-acquired pneumonia (VCAP), including COVID-19, bronchiolitis (BRO), nontuberculous mycobacteria (NTM) lung infection and various severe lung infections with underlying chronic obstructive pulmonary disease (COPD). Its LungFit PH is an ionizer technology that generates on-demand NO from ambient air and, regardless of dose or flow, delivers it to a ventilator circuit. The LungFit can generate up to 400 parts per million (ppm) of NO.


NDAQ:XAIR - Post by User

Beyond Air Inc
Bullboard Posts
Next >>
User Avatar Image
(4)
•••
  • AviseAnalyticsX
Post by AviseAnalyticson Aug 30, 2021 7:48am
107 Views
Post# 33780658

BEYOND AIR: STRONG UPCOMING CATALYSTS MAKE THIS A MUST WATCH

BEYOND AIR: STRONG UPCOMING CATALYSTS MAKE THIS A MUST WATCH
Beyond Air (NASDAQ:XAIR) is a clinical-stage biopharmaceutical and medical device company that uses a proprietary technology to produce nitric oxide from ambient air through its LungFit System.
 
The Company has major upcoming catalysts that include the US FDA approval of LungFit:registered: PH ventilator compatible and interim data readouts from Acute viral pneumonia (including COVID19) and Nontuberculous mycobacteria (NTM) lung infection. The Company intends to launch e first in human studies in Multiple Solid Tumors by the end of 2021.
 
The Company's breakthrough technology can be a potential disruptor in the delivery of Nitric Oxide!
 
Read on to find out more!

Learn more
 
https://www.aviseanalytics.com/beyond-air-strong-upcoming-catalysts-make-this-a-must-watch/
Bullboard Posts
Next >>